Search

Your search keyword '"Hernandez Perez, Miguel Angel"' showing total 16 results
Start Over Author "Hernandez Perez, Miguel Angel"
16 results on '"Hernandez Perez, Miguel Angel"'

1. Perceived illness-related uncertainty among patients with mid-stage relapsing-remitting multiple sclerosis

Author

Sabin, Julia, Salas, Elisa, Martín-Martínez, Jesús, Candeliere-Merlicco, Antonio, Barrero, Francisco Javier, Alonso, Ana, Sánchez-Menoyo, José Luis, Borrega, Laura, Rodríguez-Rodríguez, María, Gómez-Gutiérrez, Montserrat, Eichau, Sara, Hernández-Pérez, Miguel Ángel, Calles, Carmen, Fernández-Díaz, Eva, Carmona, Olga, Orviz, Aida, López-Real, Ana, López-Muñoz, Pablo, Mendonza, Amelia, Agüera, Eduardo, and Maurino, Jorge

Published
2024
Full Text
View/download PDF

2. Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study

Author

Oreja-Guevara, Celia, Meca-Lallana, José E., Díaz-Díaz, Judit, Ara, José-Ramón, Hernández Pérez, Miguel Ángel, Gracia Gil, Julia, Alonso Torres, Ana María, Pilo de la Fuente, Belén, Ramió-Torrentà, Lluís, Eichau Madueño, Sara, Gascón-Giménez, Francisco, Casanova, Bonaventura, Martínez-Yélamos, Sergio, Aguado Valcárcel, Marta, Martínez Ginés, Maria Luisa, El Berdei Montero, Yasmina, López Real, Ana María, González-Quintanilla, Vicente, De Torres, Laura, Martínez-Rodríguez, José Enrique, Costa-Frossard, Lucienne, Garcés Redondo, Moisés, Labiano Fontcuberta, Andrés, Castellanos-Pinedo, Fernando, García Merino, Juan Antonio, Muñoz Fernández, Carmen, Castillo-Triviño, Tamara, Meca-Lallana, Virginia, Peña Martínez, Joaquín, Rodríguez-Antigüedad, Alfredo, Prieto González, José María, Agüera Morales, Eduardo, Pérez Molina, Inmaculada, Solar Sánchez, Dulce M, Herrera Varo, Nicolás, Romero Sevilla, Raúl, Gómez Vicente, Lidia, and Río, Jordi

Published
2024
Full Text
View/download PDF

3. Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Author

Singer, Barry A, primary, Arnold, Douglas L, additional, Drulovic, Jelena, additional, Freedman, Mark S, additional, Gold, Ralf, additional, Gudesblatt, Mark, additional, Jasinska, Elzbieta, additional, LaGanke, Christopher C, additional, Naismith, Robert T, additional, Negroski, Donald, additional, Oh, Jiwon, additional, Hernandez Perez, Miguel Angel, additional, Selmaj, Krzysztof, additional, Then Bergh, Florian, additional, Wundes, Annette, additional, Ziemssen, Tjalf, additional, Castro-Borrero, Wanda, additional, Chen, Hailu, additional, Levin, Seth, additional, Scaramozza, Matthew, additional, Shankar, Sai L, additional, Wang, Ting, additional, and Wray, Sibyl, additional

Published
2023
Full Text
View/download PDF

4. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Author

Bartholomé, Emmanuel, D'Hooghe, Marie, Pandolfo, Massimo, Van Wijmeersch, Bart, Bhan, Virender, Blevins, Gregg, Brunet, Donald, Devonshire, Virginia, Duquette, Pierre, Freedman, Mark, Grand'Maison, François, Jacques, François, Lapierre, Yves, Lee, Liesly, Morrow, Sarah, Yeung, Michael, Dufek, Michal, Havrdová, Eva Kubala, Kanovsky, Petr, Stetkarova, Ivana, Talabova, Marika, Frederiksen, Jette, Kant, Matthias, Petersen, Thor, Ravnborg, Mads, Sellebjerg, Finn, Airas, Laura, Elovaara, Irina, Eralinna, Juha-Pekka, Sarasoja, Taneli, Al Khedr, Abdullatif, Brassat, David, Brochet, Bruno, Camu, William, Debouverie, Marc, Laplaud, David, Lebrun Frenay, Christine, Pelletier, Jean, Vermersch, Patrick, Vukusi, Sandra, Baum, Karl, Berthele, Achim, Faiss, Juergen, Flachenecker, Peter, Hohlfeld, Reinhard, Krumbholz, Markus, Lassek, Christoph, Maeurer, Mathias, Meuth, Sven, Ziemssen, Tjalf, Hardiman, Orla, McGuigan, Christopher, Achiron, Anat, Karussis, Dimitrios, Bergamaschi, Roberto, Morra, Vincenzo Brescia, Comi, Giancarlo, Cottone, Salvatore, Grimaldi, Luigi, Mancardi, Giovanni Luigi, Massacesi, Luca, Nocentini, Ugo, Salvetti, Marco, Scarpini, Elio, Sola, Patrizia, Tedeschi, Gioacchino, Trojano, Maria, Zaffaroni, Mauro, Frequin, Stephan, Hupperts, Raymond, Killestein, Joep, Schrijver, Hans, Van Dijl, Ronald, van Munster, Erik, Czarnecki, Maciej, Drozdowski, Wieslaw, Fryze, Waldemar, Hertmanowska, Hanka, Ilkowski, Jan, Kaminska, Anna, Klodowska-Duda, Gabriela, Maciejowski, Maciej, Motta, Ewa, Podemski, Ryszard, Potemkowski, Andrzej, Rog, Teresa, Selmaj, Krzysztof, Stelmasiak, Zbigniew, Stepien, Adam, Tutaj, Andrzej, Zaborski, Jacek, Boyko, Alexey, Chefranova, Zanna, Evdoshenko, Evgeny, Khabirov, Farit, Sivertseva, Stella, Yakupov, Eduard, Alvarez Cermeño, Jose Carlos, Escartin, Antonio, Fernandez, Oscar Fernandez, Garcia-Merino, Antonio, Hernandez Perez, Miguel Angel, Ayuso, Guillermo Izquierdo, Lallana, José Meca, Gairin, Xavier Montalban, Oreja-Guevara, Celia, Saiz Hinarejos, Albert, Gunnarsson, Martin, Lycke, Jan, Martin, Claes, Piehl, Fredrik, Roshanisefat, Homayoun, Sundstrom, Peter, Duddy, Martin, Gran, Bruno, Harrower, Timothy, Hobart, Jeremy, Kapoor, Raju, Lee, Martin, Mattison, Paul, Nicholas, Richard, Pearson, Owen, Rashid, Waqar, Rog, David, Sharrack, Basil, Silber, Eli, Turner, Ben, Williams, Anna, Woolmore, John, Young, Carolyn, Bandari, Daniel, Berger, Joseph, Camac, Ann, Cohan, Stanley, Conway, Jill, Edwards, Keith, Fabian, Michelle, Florin, Jack, Freedman, Steven, Garwacki, Dennis, Goldman, Myla, Harrison, Daniel, Herrman, Craig, Huang, Deren, Javed, Adil, Jeffery, Douglas, Kamin, Stephen, Katsamakis, George, Khatri, Bhupendra, Langer-Gould, Annette, Lynch, Sharon, Mattson, David, Miller, Tamara, Miravalle, Augusto, Moses, Harold, Muley, Suraj, Napier, James, Nielsen, Allen, Pachner, Andrew, Pardo, Gabriel, Picone, MaryAnn, Robertson, Derrick, Royal, Walter, Sheppard, Christopher, Thrower, Ben, Twyman, Cary, Waubant, Emmanuelle, Wendt, Jeanette, Yadav, Vijayshree, Zabad, Rana, Zarelli, Greg, Ho, Pei-Ran, Campbell, Nolan, Chang, Ih, Deykin, Aaron, Forrestal, Fiona, Lucas, Nisha, Yu, Bei, Arnold, Douglas L, Freedman, Mark S, Goldman, Myla D, Hartung, Hans-Peter, Miller, Aaron, Cadavid, Diego, Mikol, Dan, and Steiner, Deborah

Published
2018
Full Text
View/download PDF

11. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Author

Kapoor, Raju, primary, Ho, Pei-Ran, additional, Campbell, Nolan, additional, Chang, Ih, additional, Deykin, Aaron, additional, Forrestal, Fiona, additional, Lucas, Nisha, additional, Yu, Bei, additional, Arnold, Douglas L, additional, Freedman, Mark S, additional, Goldman, Myla D, additional, Hartung, Hans-Peter, additional, Havrdová, Eva Kubala, additional, Jeffery, Douglas, additional, Miller, Aaron, additional, Sellebjerg, Finn, additional, Cadavid, Diego, additional, Mikol, Dan, additional, Steiner, Deborah, additional, Bartholomé, Emmanuel, additional, D'Hooghe, Marie, additional, Pandolfo, Massimo, additional, Van Wijmeersch, Bart, additional, Bhan, Virender, additional, Blevins, Gregg, additional, Brunet, Donald, additional, Devonshire, Virginia, additional, Duquette, Pierre, additional, Freedman, Mark, additional, Grand'Maison, François, additional, Jacques, François, additional, Lapierre, Yves, additional, Lee, Liesly, additional, Morrow, Sarah, additional, Yeung, Michael, additional, Dufek, Michal, additional, Kanovsky, Petr, additional, Stetkarova, Ivana, additional, Talabova, Marika, additional, Frederiksen, Jette, additional, Kant, Matthias, additional, Petersen, Thor, additional, Ravnborg, Mads, additional, Airas, Laura, additional, Elovaara, Irina, additional, Eralinna, Juha-Pekka, additional, Sarasoja, Taneli, additional, Al Khedr, Abdullatif, additional, Brassat, David, additional, Brochet, Bruno, additional, Camu, William, additional, Debouverie, Marc, additional, Laplaud, David, additional, Lebrun Frenay, Christine, additional, Pelletier, Jean, additional, Vermersch, Patrick, additional, Vukusi, Sandra, additional, Baum, Karl, additional, Berthele, Achim, additional, Faiss, Juergen, additional, Flachenecker, Peter, additional, Hohlfeld, Reinhard, additional, Krumbholz, Markus, additional, Lassek, Christoph, additional, Maeurer, Mathias, additional, Meuth, Sven, additional, Ziemssen, Tjalf, additional, Hardiman, Orla, additional, McGuigan, Christopher, additional, Achiron, Anat, additional, Karussis, Dimitrios, additional, Bergamaschi, Roberto, additional, Morra, Vincenzo Brescia, additional, Comi, Giancarlo, additional, Cottone, Salvatore, additional, Grimaldi, Luigi, additional, Mancardi, Giovanni Luigi, additional, Massacesi, Luca, additional, Nocentini, Ugo, additional, Salvetti, Marco, additional, Scarpini, Elio, additional, Sola, Patrizia, additional, Tedeschi, Gioacchino, additional, Trojano, Maria, additional, Zaffaroni, Mauro, additional, Frequin, Stephan, additional, Hupperts, Raymond, additional, Killestein, Joep, additional, Schrijver, Hans, additional, Van Dijl, Ronald, additional, van Munster, Erik, additional, Czarnecki, Maciej, additional, Drozdowski, Wieslaw, additional, Fryze, Waldemar, additional, Hertmanowska, Hanka, additional, Ilkowski, Jan, additional, Kaminska, Anna, additional, Klodowska-Duda, Gabriela, additional, Maciejowski, Maciej, additional, Motta, Ewa, additional, Podemski, Ryszard, additional, Potemkowski, Andrzej, additional, Rog, Teresa, additional, Selmaj, Krzysztof, additional, Stelmasiak, Zbigniew, additional, Stepien, Adam, additional, Tutaj, Andrzej, additional, Zaborski, Jacek, additional, Boyko, Alexey, additional, Chefranova, Zanna, additional, Evdoshenko, Evgeny, additional, Khabirov, Farit, additional, Sivertseva, Stella, additional, Yakupov, Eduard, additional, Alvarez Cermeño, Jose Carlos, additional, Escartin, Antonio, additional, Fernandez, Oscar Fernandez, additional, Garcia-Merino, Antonio, additional, Hernandez Perez, Miguel Angel, additional, Ayuso, Guillermo Izquierdo, additional, Lallana, José Meca, additional, Gairin, Xavier Montalban, additional, Oreja-Guevara, Celia, additional, Saiz Hinarejos, Albert, additional, Gunnarsson, Martin, additional, Lycke, Jan, additional, Martin, Claes, additional, Piehl, Fredrik, additional, Roshanisefat, Homayoun, additional, Sundstrom, Peter, additional, Duddy, Martin, additional, Gran, Bruno, additional, Harrower, Timothy, additional, Hobart, Jeremy, additional, Kapoor, Raju, additional, Lee, Martin, additional, Mattison, Paul, additional, Nicholas, Richard, additional, Pearson, Owen, additional, Rashid, Waqar, additional, Rog, David, additional, Sharrack, Basil, additional, Silber, Eli, additional, Turner, Ben, additional, Williams, Anna, additional, Woolmore, John, additional, Young, Carolyn, additional, Bandari, Daniel, additional, Berger, Joseph, additional, Camac, Ann, additional, Cohan, Stanley, additional, Conway, Jill, additional, Edwards, Keith, additional, Fabian, Michelle, additional, Florin, Jack, additional, Freedman, Steven, additional, Garwacki, Dennis, additional, Goldman, Myla, additional, Harrison, Daniel, additional, Herrman, Craig, additional, Huang, Deren, additional, Javed, Adil, additional, Kamin, Stephen, additional, Katsamakis, George, additional, Khatri, Bhupendra, additional, Langer-Gould, Annette, additional, Lynch, Sharon, additional, Mattson, David, additional, Miller, Tamara, additional, Miravalle, Augusto, additional, Moses, Harold, additional, Muley, Suraj, additional, Napier, James, additional, Nielsen, Allen, additional, Pachner, Andrew, additional, Pardo, Gabriel, additional, Picone, MaryAnn, additional, Robertson, Derrick, additional, Royal, Walter, additional, Sheppard, Christopher, additional, Thrower, Ben, additional, Twyman, Cary, additional, Waubant, Emmanuelle, additional, Wendt, Jeanette, additional, Yadav, Vijayshree, additional, Zabad, Rana, additional, and Zarelli, Greg, additional

Published
2018
Full Text
View/download PDF

15. Study of the Protective Capability of a SiO2 Nanolayer over a Copper Sulphate Patina

Author

Jimenez- Sanchez, Tania, Galvan-Martinez, Ricardo, Fajardo, Gerardo, Cruz Moreno, Dulce, Hernandez-Perez, Miguel Angel, and Orozco-Cruz, Ricardo

Abstract

In this work, the application of a nanocovering of SiO2on artificial sulphate patina and exposed to the atmosphere was sprayed with the objective of analyzing the degradation mechanisms and protective capability. The development of the nanocovering was carried out by sol-gel synthesis using as a precursor Orto Tetraethylsilicate (TEOS). The morphological and structural characterization of nanocoating was performed using Scanning Electron Microscopy (MEB) and X-ray Diffraction (DRX), resulting in an amorphous structure of SiO2and nanoparticle sizes from 82.7 to 92.4 nm. The nanocovering was evaluated using the electrochemical techniques of Polarization Resistance (Rp) and Electrochemical Impedance Spectroscopy (EIE) using a 3.5% NaCl gelled cell and agar as electrolyte. The electrochemical behavior of the coating in the first days showed an increase in the Rtc, after the week of exposure a decrease in the protective properties of the nano coating was observed.

Published
2019
Full Text
View/download PDF

16. Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.

Author

Singer BA, Arnold DL, Drulovic J, Freedman MS, Gold R, Gudesblatt M, Jasinska E, LaGanke CC, Naismith RT, Negroski D, Oh J, Hernandez Perez MA, Selmaj K, Then Bergh F, Wundes A, Ziemssen T, Castro-Borrero W, Chen H, Levin S, Scaramozza M, Shankar SL, Wang T, and Wray S

Subjects
Adult, Humans, Immunosuppressive Agents adverse effects, Dimethyl Fumarate adverse effects, Recurrence, Multiple Sclerosis, Relapsing-Remitting drug therapy, Multiple Sclerosis drug therapy
Abstract

Background: Diroximel fumarate (DRF) is approved for adults with relapsing-remitting multiple sclerosis (RRMS) in Europe and for relapsing forms of MS in the United States. DRF and dimethyl fumarate (DMF) yield bioequivalent exposure of the active metabolite monomethyl fumarate. Prior studies indicated fewer gastrointestinal (GI)-related adverse events (AEs) with DRF compared with DMF., Objective: To report final outcomes from EVOLVE-MS-1., Methods: EVOLVE-MS-1 was an open-label, 96-week, phase 3 study assessing DRF safety, tolerability, and efficacy in patients with RRMS. The primary endpoint was safety and tolerability; efficacy endpoints were exploratory., Results: Overall, 75.7% (800/1057) of patients completed the study; median exposure was 1.8 (range: 0.0-2.0) years. AEs occurred in 938 (88.7%) patients, mostly of mild (28.9%) or moderate (50.3%) severity. DRF was discontinued due to AEs in 85 (8.0%) patients, with < 2% discontinuing due to GI or flushing/flushing-related AEs. At Week 96, mean number of gadolinium-enhancing lesions was significantly reduced from baseline (72.7%; p < 0.0001); adjusted annualized relapse rate was 0.13 (95% confidence interval: 0.11-0.15)., Conclusion: DRF was generally well tolerated over 2 years, with few discontinuations due to AEs; radiological measures indicated decreased disease activity from baseline. These outcomes support DRF as a treatment option in patients with RRMS., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: BAS: research grant support from AbbVie, Biogen, Bristol Myers Squibb, Greenwich Biosciences, Novartis, and Sanofi and consulting and/or speaking fees from Alexion, Biogen, Bristol Myers Squibb, Cigna, Cycle, EMD Serono, Genentech, Horizon, Janssen, Novartis, Octave Bioscience, Roche, Sanofi, and TG Therapeutics.DLA: consulting fees from Albert Charitable Trust, Alexion Pharma, Biogen, Celgene, Frequency Therapeutics, Genentech, Med-Ex Learning, Merck, Novartis, Population Council, Receptos, Roche, and Sanofi-Aventis; grants from Biogen, Immunotec, and Novartis; and equity interest in NeuroRx.JD: advisory boards for Amicus, Biogen, Janssen, Medis, Merck, Novartis, Roche, Sanofi-Genzyme, and Teva; speaker bureaus for Biogen, Bayer, Hemofarm, Janssen, Medis, Medtronic, Merck, Novartis, Roche, Sanofi-Genzyme, Teva, and Zentiva; and research grant from Roche.MSF: research/educational grants from Sanofi-Genzyme; honoraria/consultation fees from Alexion/AstraZeneca, BMS (Celgene), EMD Serono, Hoffman La-Roche, Actelion/Janssen (J&J), Novartis, Quanterix, Sanofi-Genzyme, and Teva Canada Innovation; advisory boards/boards of directors for Alexion/AstraZeneca, Atara Biotherapeutics, Bayer Healthcare, Celestra Health, Hoffman La-Roche, Actelion/Janssen (J&J), EMD Serono/Merck Serono, Novartis, and Sanofi-Genzyme; and participated in speakers bureau for Sanofi-Genzyme and EMD Serono.RG: research support and speaker’s honoraria from Bayer-Schering, Biogen Idec, BMS, Chugai, Eisai, Genesis, Janssen, Merck Serono, Nikkiso Pharma, Novartis, Roche, Sanofi-Genzyme, Sandoz, and Teva; consulting honoraria from ZLB Behring, Baxter, Roche, and Talecris; and personal stock options in Bayer, Merck, and Roche.MG: consulting fees from Biogen, EMD Serono, Novartis, and Sanofi-Genzyme; research support from Alkermes; and speaker bureaus for Biogen, EMD Serono, Genentech-Roche, and Sanofi-Genzyme.EJ: advisory boards for Biogen and speaker fees from Biogen, Novartis, Roche, and Sanofi.CLG: consultant/advisory boards/speaker bureaus for Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Janssen, Novartis, Sanofi-Genzyme, and TG Therapeutics.RTN: consultant for Abata Therapeutics, Banner Life Sciences, BeiGene, Biogen, Bristol Myers Squibb, Genentech, Genzyme, GW Therapeutics, Janssen, Horizon Therapeutics, Lundbeck, NervGen, and TG Therapeutics.DN: research support from and consultant/advisory boards/speaker bureaus for Adamas, Alkermes, Alexion, Bayer, Biogen, Celgene/BMS, EMD Serono, Janssen, Novartis, Roche-Genentech, and Sanofi-Genzyme.JO: research support from Biogen Idec, EMD Serono, and Roche and personal compensation for consulting/speaking from Biogen Idec, BMS, EMD Serono, Eli Lilly, Roche, Sanofi-Genzyme, and Novartis.MAHP: consultant/advisory boards/speaker bureaus for Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Janssen, Novartis, Sanofi-Genzyme, and TG Therapeutics.KS: research support from Merck; advisory boards for Biogen, Celgene/BMS, Merck, Novartis, Roche, Sanofi, and TG Therapeutics.FTB: research support and travel grants, through his institution, from the German Science Fund (DFG), German Federal Ministry of Education and Science (BMBF), Bayer-Schering, Merck, Novartis, Pfizer, Roche, Sanofi, and Teva and speaker fees from and advisory boards for Actelion, Alexion, Bayer, Biogen, CSL Behring, Fresenius, Horizon, Merck, Novartis, Roche, Sanofi-Genzyme, and Teva.AW: adviser fees from AbbVie and research support from AbbVie, Alkermes, and Biogen.TZ: personal compensation for consulting services and speaker honoraria from Bayer, Biogen Idec, Novartis, Sanofi, Synthon, and Teva and financial support for research activities from Bayer, Biogen Idec, Novartis, Sanofi-Aventis, and Teva.WC-B, HC, SL, MS, SLS, and TW: employees of and hold stock/stock options in Biogen.SW: consulting fees from and advisory boards for Biogen, Celgene, and EMD Serono; speaker bureaus for Biogen, Celgene, EMD Serono, Roche-Genentech, and Sanofi-Genzyme; and research support from Biogen, Celgene, EMD Serono, Novartis, Receptos, Roche-Genentech, Sanofi-Genzyme, and TG.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results